VGSK Technologies Inc

VGSK is excited to post our work on lung inflammation and COVID-19 in bioRxiv

ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation Background Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant. ProLung™-budesonide may offer anti-inflammatory and protective effects to the lung in COVID-19, ye...

10 day countdown to and during !
Contact us today to set up a meeting and learn about our single dose drug delivery system. Hope to see you there!